Antibe Therapeutics (OTCQB: ATBPF) CEO Daniel Legault chats with Proactive Investors' Steve Darling at the 9th Annual LD Micro Invitational Investor Conference in Los Angeles, CA. The healthcare company focuses on the development of patents and out-licensing of improved compounds of existing drugs.
Antibe Therapeutics targets opioids with post-op pain drug
Quick facts: Antibe Therapeutics, Inc.
Price: 0.62 CAD
Market Cap: $169.99 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics, Inc. named herein, including the promotion by the Company of Antibe Therapeutics, Inc. in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE